Literature DB >> 8531887

Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines.

E AlonsoDeVelasco1, A F Verheul, J Verhoef, H Snippe.   

Abstract

Although pneumococcal conjugate vaccines are close to being licensed, a more profound knowledge of the virulence factors responsible for the morbidity and mortality caused by Streptococcus pneumoniae is necessary. This review deals with the major structures of pneumococci involved in the pathogenesis of pneumococcal disease and their interference with the defense mechanisms of the host. It is well known that protection against S. pneumoniae is the result of phagocytosis of invading pathogens. For this process, complement and anticapsular polysaccharide antibodies are required. Besides, relatively recent experimental data suggest that protection is also mediated by the removal of disintegrating pneumococci and their degradation products (cell wall, pneumolysin). These structures seem to be major contributors to illness and death caused by pneumococci. An effective conjugate vaccine should therefore preferably include the capsular polysaccharide and at least one of these inflammatory factors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8531887      PMCID: PMC239389          DOI: 10.1128/mr.59.4.591-603.1995

Source DB:  PubMed          Journal:  Microbiol Rev        ISSN: 0146-0749


  158 in total

1.  Activation of the alternative pathway by pneumococcal cell walls.

Authors:  J A Winkelstein; A Tomasz
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

2.  Western blot analysis of immunoglobulin G antibodies to pneumococcal protein antigens in healthy adults.

Authors:  J Renneberg; M Svinhufvud; K Prellner; P Christensen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

3.  Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?

Authors:  D M Musher; D A Watson; R E Baughn
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

Review 4.  Chronic granulomatous disease.

Authors:  R B Johnston; S L Newman
Journal:  Pediatr Clin North Am       Date:  1977-05       Impact factor: 3.278

5.  Degradation of C3 by Streptococcus pneumoniae.

Authors:  C S Angel; M Ruzek; M K Hostetter
Journal:  J Infect Dis       Date:  1994-09       Impact factor: 5.226

6.  Susceptibility of Streptococcus pneumoniae to penicillin: a prospective microbiological and clinical study.

Authors:  M E García-Leoni; E Cercenado; P Rodeño; J C Bernaldo de Quirós; D Martínez-Hernández; E Bouza
Journal:  Clin Infect Dis       Date:  1992-02       Impact factor: 9.079

7.  Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution.

Authors:  J H van de Wijgert; A F Verheul; H Snippe; I J Check; R L Hunter
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

8.  Serotypes of Streptococcus pneumoniae causing disease.

Authors:  B M Gray; G M Converse; H C Dillon
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

9.  Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine.

Authors:  T Barington; A Gyhrs; K Kristensen; C Heilmann
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

10.  Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2.

Authors:  A W Griffioen; G T Rijkers; P Janssens-Korpela; B J Zegers
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

View more
  121 in total

1.  Characterization of the type 8 capsular gene cluster of Streptococcus pneumoniae.

Authors:  R Muñoz; M Mollerach; R López; E García
Journal:  J Bacteriol       Date:  1999-10       Impact factor: 3.490

Review 2.  Streptococcus pneumoniae.

Authors:  J R Catterall
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

3.  Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F.

Authors:  A H Lucas; K D Moulton; V R Tang; D C Reason
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses.

Authors:  K Overweg; A Kerr; M Sluijter; M H Jackson; T J Mitchell; A P de Jong; R de Groot; P W Hermans
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

5.  Genetic relatedness within serotypes of penicillin-susceptible Streptococcus pneumoniae isolates.

Authors:  K Overweg; D Bogaert; M Sluijter; J Yother; J Dankert; R de Groot; P W Hermans
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

6.  Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis.

Authors:  Johann S Braun; Jack E Sublett; Dorette Freyer; Tim J Mitchell; John L Cleveland; Elaine I Tuomanen; Joerg R Weber
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

7.  Induction of gamma interferon and nitric oxide by truncated pneumolysin that lacks pore-forming activity.

Authors:  Hisashi Baba; Ikuo Kawamura; Chikara Kohda; Takamasa Nomura; Yutaka Ito; Terumi Kimoto; Isao Watanabe; Satoshi Ichiyama; Masao Mitsuyama
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

8.  Serotyping Streptococcus pneumoniae by multiplex PCR.

Authors:  D A Brito; M Ramirez; H de Lencastre
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

9.  Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells.

Authors:  S Romero-Steiner; D Libutti; L B Pais; J Dykes; P Anderson; J C Whitin; H L Keyserling; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

10.  Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides.

Authors:  W R Usinger; A H Lucas
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.